Some tumors with specific oncogenic addictions (for example fusion proteins leading to ALK expression in lung cancer or Bcr-Abl in chronic myeloid leukemia, KIT expression or mutations in GIST or EGFR mutation in lung cancer, HER2 amplification in breast cancer or MET overexpression in liver tumors) greatly benefited from targeted agents. This evidence concerns the gene KIT and lung carcinoma.